Lipid and vascular biomarker responses to sulfated chitosan in rabbits with experimental hypercholesterolemia
Keywords:
sulfated chitosan; sulfoparin; hypercholesterolemia; rabbit; lipoproteins; vascular biomarkersAbstract
Sulfation modifies the biological properties of chitosan and may produce compounds with activity relevant to vascular disease. The efficacy of an individual preparation requires evaluation independently of findings for other chitosan derivatives. Objective: To describe the lipid and circulating vascular biomarker responses associated with a locally synthesized sulfated chitosan preparation, designated sulfoparin, in cholesterol-exposed rabbits. Methods: Aggregate endpoint data were extracted from a dissertation reporting 46 Chinchilla rabbits allocated to an intact group (n = 6) and five cholesterol-exposed groups (n = 8 each). After two months of cholesterol exposure, treatment continued for one month alongside cholesterol administration. Groups received no active treatment, a fibrate comparator reported as “hemfibrazil” at 100 mg/kg, heparin at 15 IU/kg, or sulfated chitosan at reported doses of 25 or 50 μg/kg. Treatment routes and the unusually low chitosan dose units require verification. Results: Compared descriptively with untreated hypercholesterolemia, sulfated chitosan at the two reported doses was associated with 53.9% and 55.4% lower total cholesterol, 71.7% and 74.4% lower LDL cholesterol, and 73.1% and 78.3% lower C-reactive protein. NOx was 12.29 and 17.86 μmol/L, respectively, compared with 7.89 μmol/L in untreated animals and 16.68 μmol/L in intact animals. Homocysteine remained numerically above the intact reference at both doses. No new inferential statistics were calculated. Conclusions: The source tables describe substantial lipid and biomarker differences associated with sulfated chitosan treatment. These findings support confirmatory investigation but do not establish clinical efficacy, equivalence to heparin, functional endothelial recovery or an optimal dose. Verification of the compound, dosing records, assays and raw data is essential.
References
1.Vongchan P, Sajomsang W, Subyen D, Kongtawelert P. Anticoagulant activity of a sulfated chitosan. Carbohydr Res. 2002;337:1239–1242. https://pubmed.ncbi.nlm.nih.gov/12110200/
2.Suwan J, Zhang Z, Li B, et al. Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activity. Carbohydr Res. 2009;344(10):1190–1196. https://doi.org/10.1016/j.carres.2009.04.016
3.[Author, official title, institution and year to be supplied]. Dissertation supplied as “дисс инглиз(1).docx”. Chapters 2 and 4, Tables 4.1–4.3. Primary source document; bibliographic identity unconfirmed.
4.Keaney JF Jr, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. J Clin Invest. 1995;95(6):2520–2529. https://doi.org/10.1172/JCI117953
5.Percie du Sert N, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. https://doi.org/10.1371/journal.pbio.3000410
6.International Committee of Medical Journal Editors. Overlapping publications. Accessed 13 October 2026. https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/overlapping-publications.html.
7.Qutlikova G.M., Yuldashev R.N., Xudayarova N.K., Vakhobov Kh.B., Ganieva N.A.Temporal changes in inflammatory and nitric oxide related biomarkers in rabbits with experimental hypercholesterolemia. Egyptian Medical Journal of theNational ResearchCenter ISSN:2090-5386 Impactfactor:12.3. http://www.mjnrc.com/index.php/emjn .




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal